Condition: HCC · Sponsor: Peking University
This is a Phase I clinical study evaluating the safety, pharmacokinetics, and initial efficacy of a GPC3-targeted chimeric antigen receptor autologous T cell injection (OriC902) in GPC3-positive advanced hepatocellular carcinoma (HCC) subjects
This description comes directly from the study's public registry record.
Changsong Qi · 13811394004 · xiwangpku@126.com
Always discuss trial participation with your own doctor first.
| Beijing GoBroad Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Cancer Hospital & Institute | Beijing, Beijing Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06891742